Connect with us

Uncategorized

German Professor Arrested After Speaking At “We Do Not Consent” Rally In London

German Professor Arrested After Speaking At "We Do Not Consent" Rally In London

Published

on

German Professor Arrested After Speaking At "We Do Not Consent" Rally In London Tyler Durden Sun, 09/27/2020 - 09:55

After Metropolitan Police claimed they would only crack down on marchers flagrantly violating social distancing rules (though the hated "rule of six" had been suspended due to the gathering's "protest" status), German professor Dr. Heiko Schoening was arrested by a gang of British officers - he was filmed being loaded into a paddy wagon -  after speaking out against using tactics like economy-destroying mandatory lockdowns during yesterday's "We Do Not Consent" rally in London.

Video of the arrest was shared on Twitter.

Several purported bystanders tweeted in protest, by the story appears to have gone largely unnoticed.

Here's video of the doctor speaking to a reporter at the event yesterday. This was filmed before he was arrested.

 

The rally was organized by groups opposing a second lockdown in the UK, along with mandatory vaccination efforts by the government once a vaccine is approved. The doctor was pat of a group of hundreds of German doctors and scientists who have signed on to investigate and analyze whether the heavy handed measures favored by governments to combat the virus were the appropriate response.

Purported friends of the professor claimed that his wife was calling supporters to attend a peaceful demonstration on Sunday outside Wandsworth police station (146 Wandsworth High St).

Read More

Continue Reading

Uncategorized

Vera Bradley Q2 Results Miss Estimates; Shares Fall 10%

Vera Bradley (VRA) delivered second-quarter Fiscal 2022 results that fell short of Wall Street expectations. The company also warned that the retail environment remains uncertain amid supply chain challenges and
Read More…
The post Vera Bradley Q2 Resul

Published

on

Vera Bradley (VRA) delivered second-quarter Fiscal 2022 results that fell short of Wall Street expectations. The company also warned that the retail environment remains uncertain amid supply chain challenges and an increase in freight charges. VRA shares fell 9.42% to close at $10.38 on September 1.

Founded in 1982, Vera Bradley designs and sells women’s handbags, luggage, and other travel items. It also deals in home accessories and unique gifts. (See Vera Bradley stock charts on TipRanks)

Fiscal Q2 revenue increased 11.6% year-over-year to $147 million as Vera Bradley bounced back to pre-pandemic levels on a comparable basis. The increase came on customers responding to product innovations and sales for travel-related products bouncing back. However, revenue fell short of analyst expectations of $153.61 million.

Meanwhile, consolidated second-quarter net income landed at $9.5 million, or $0.28 per diluted share. Analysts were expecting earnings of $0.33 a share.

According to CEO Rob Wallstrom, Pura Vida revenues were negatively affected by the Apple iOS 14.5 update. The update impacted Facebook and Instagram advertising, which have been vital in driving sales.

Wallstrom stated, “Our team is working diligently to quickly diversify a portion of our marketing resources to other platforms, and consequently, we began to see Pura Vida direct-to-consumer sales volume build momentum throughout the balance of the second quarter and into the beginning of the third.”

For Fiscal 2022 Vera Bradley expects revenues to land at between $550 million and $565 million compared to $468.3 million delivered in Fiscal 2021. Consolidated diluted EPS is expected at between $0.80 and $0.95 compared to $0.63 for Fiscal 2021.

In June, Robert W. Baird analyst Mark Altschwager reiterated a Hold rating on the stock with a $14 price target, implying 34.87% upside potential to current levels.

Consensus among analysts is a Moderate Buy based on 1 Buy and 2 holds. The average Vera Bradley price target of $15 implies 44.51% upside potential to current levels.

VRA scores 8 out of 10 on TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations.

Related News:
TerrAscend to Buy Premium Cannabis Operator Gage Growth
ATS Acquires NCC Automated Systems for $40M
Komatsu Rallies After Second Cathie Wood ETF Buys Stock

The post Vera Bradley Q2 Results Miss Estimates; Shares Fall 10% appeared first on TipRanks Financial Blog.

Read More

Continue Reading

Science

Avricore Health Signs Master Agreement to Pilot HEALTHTAB™ Platform For Diabetes Management in Select Shoppers Drug Mart® Pharmacies

Avricore Health (AVCR) announces that patients will soon have access to its innovative point-of-care blood screening and health-data management platform, HealthTab™…

Published

on

VANCOUVER, BC – (GLOBE NEWSWIRE)  June 3, 2021 Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce patients will soon have access to its innovative point-of-care blood screening and health-data management platform, HealthTab™, at select Shoppers Drug Mart locations. Through this pilot program, patients will have greater access to earlier diabetes detection and preventative screening services for at-risk individuals. Ultimately, the objective is to reduce the negative health impacts and support those living with diabetes achieve higher quality-of-life.

The program, as per the Master Agreement Statement of Work, will launch in eleven Shoppers Drug Mart locations in Ontario with HealthTab™-integrated Afinion2™ analyzers by Abbott Diagnostics to refine workflow and engagement approaches.  Pharmacists will test patients’ average blood sugar (HbA1C) and lipids with results reported via the cloud-based HealthTab™ system. 

“Having accessible, high-quality diagnostics with real-time data reporting and the support of a trusted Shoppers Drug Mart pharmacist is a powerful combination in the battle against chronic disease in Canada,” said Hector Bremner, CEO of Avricore Health. “This initiative is a major step forward for our mission to deliver the most accessible early disease detection and management platform in the country.”

The program’s initial focus is to screen patients at-risk for developing diabetes and cardiovascular conditions and to support those already diagnosed by a physician to better manage their conditions for higher quality of life.

“Our purpose is to help Canadians live life well and that means providing the tools and services they need to successfully manage their overall health. Lowering barriers to health information and getting more support from a qualified health professional, like one of our pharmacists, are important steps forward in mitigating disease impacts and increasing patient quality of life,” said Doug Bryce, VP, Health & Pharmacy Programs and Innovation, Shoppers Drug Mart. “We’re committed to innovations in service because it allows us to better support our customers. The HealthTab™ Diabetes platform will provide our patients living with Diabetes new program options to better manage their conditions.”

This initiative builds off the past success of HealthTab™ used in a government-funded screening program for Chronic Kidney Disease (CKD) in Canadian pharmacies.

Learn more at: https://corporate.shoppersdrugmart.ca

 

About HealthTab™ + RASTR

HealthTab™ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTabÔ  test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick.  Results can be printed in-store or accessed securely online.

As part of this direction for HealthTab™ the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab™ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities.  This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.  

And, with the emergence of COVID-19 and its variants, the HealthTab™ + RASTR platform can now directly report results from the Abbott ID Now™, or manually report results from rapid-tests, dramatically reducing the administration time and increasing the accuracy and speed of information sharing.

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company’s goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

 

Contact:

Avricore Health Inc.

Hector Bremner, CEO 604-773-8943

info@avricorehealth.com

www.avricorehealth.com

 

Cautionary Note Regarding Forward-Looking Statements

Information in this press release that involves Avricore Health’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy 

Ira Rotenberg
Author: Ira Rotenberg

Continue Reading

Uncategorized

“Next Level Dystopian Sh*t”: Amazon Rolls Out Portable Panic Booth For Warehouse Employees To Collect Themselves

"Next Level Dystopian Sh*t": Amazon Rolls Out Portable Panic Booth For Warehouse Employees To Collect Themselves

After years of reports of Amazon warehouse employees being forced to urinate in bottles, forego medical care, and work through…

Published

on

"Next Level Dystopian Sh*t": Amazon Rolls Out Portable Panic Booth For Warehouse Employees To Collect Themselves

After years of reports of Amazon warehouse employees being forced to urinate in bottles, forego medical care, and work through injuries - causing hundreds to launch petitions and revolt, the online retail giant has come up with a solution...

...a special sensory deprivation booth that allows stressed out employees to collect themselves before heading back out to the floor.

Known simply as the “ZenBooth,” the new apparatus, according to a video released by the company on Wednesday, is an “interactive kiosk where you can navigate through a library of mental health and mindful practices to recharge that internal battery.” -daily dot

The "ZenBooth" is part of Amazon's WorkingWell program, which allows employees to "recharge and reenergize" with a series of "physical and mental activities, wellness exercises, and healthy eating support."

The panic booth features a small fan, some plants, and a library of meditation videos. Hopefully it features a toilet too.

(Did we mention most COVID-19 transmission occurs via aerosolized particles hanging in the air, particularly in poorly ventilated spaces?)

As the daily dot notes, the announcement received lots of pushback from Twitter users.

"why not just improve working conditions?" said one user.

"Or you could pay your employees well, not treat them like garbage, and accept unionization," added another.

"This is some next level dystopian shit. Maybe just pay people more and let them have bathroom breaks," read yet another tweet.

At least this is a step up from their now-abandoned, patented 'worker cages.'

Tyler Durden Fri, 05/28/2021 - 19:20

Read More

Continue Reading

Trending